Takeda, Pfizer's Adcetrix wins EU approval for hodgkin lymphoma

• Takeda (NYSE:TAK) (4502.T) said on Tuesday that the European Commission approved Pfizer (NYSE:PFE) and the company's antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in adults with newly diagnosed stage IIb Hodgkin lymphoma.
• The decision follows a positive opinion